These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 25497488

  • 1. Particle engineering to enhance or lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome.
    Patel B, Gupta N, Ahsan F.
    Eur J Pharm Biopharm; 2015 Jan; 89():163-74. PubMed ID: 25497488
    [Abstract] [Full Text] [Related]

  • 2. Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages.
    Lee WH, Loo CY, Traini D, Young PM.
    Expert Opin Drug Deliv; 2015 Jun; 12(6):1009-26. PubMed ID: 25912721
    [Abstract] [Full Text] [Related]

  • 3. The application of high-content analysis in the study of targeted particulate delivery systems for intracellular drug delivery to alveolar macrophages.
    Lawlor C, O'Sullivan MP, Sivadas N, O'Leary S, Gallagher PJ, Keane J, Cryan SA.
    Mol Pharm; 2011 Aug 01; 8(4):1100-12. PubMed ID: 21591762
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Particulate systems for targeting of macrophages: basic and therapeutic concepts.
    Moghimi SM, Parhamifar L, Ahmadvand D, Wibroe PP, Andresen TL, Farhangrazi ZS, Hunter AC.
    J Innate Immun; 2012 Aug 01; 4(5-6):509-28. PubMed ID: 22722900
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Influence of particle geometry and PEGylation on phagocytosis of particulate carriers.
    Mathaes R, Winter G, Besheer A, Engert J.
    Int J Pharm; 2014 Apr 25; 465(1-2):159-64. PubMed ID: 24560647
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Distribution and Cellular Uptake of PEGylated Polymeric Particles in the Lung Towards Cell-Specific Targeted Delivery.
    Shen TW, Fromen CA, Kai MP, Luft JC, Rahhal TB, Robbins GR, DeSimone JM.
    Pharm Res; 2015 Oct 25; 32(10):3248-60. PubMed ID: 26002743
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Shielding Therapeutic Drug Carriers from the Mononuclear Phagocyte System: A Review.
    Sathyamoorthy N, Dhanaraju MD.
    Crit Rev Ther Drug Carrier Syst; 2016 Oct 25; 33(6):489-567. PubMed ID: 27992308
    [Abstract] [Full Text] [Related]

  • 19. PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin.
    Patel B, Gupta V, Ahsan F.
    J Control Release; 2012 Sep 10; 162(2):310-20. PubMed ID: 22800582
    [Abstract] [Full Text] [Related]

  • 20. Delivery strategies for sustained drug release in the lungs.
    Loira-Pastoriza C, Todoroff J, Vanbever R.
    Adv Drug Deliv Rev; 2014 Aug 10; 75():81-91. PubMed ID: 24915637
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.